These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26295137)

  • 1. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
    Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
    Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
    Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.
    Shi JF; Sun MG; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Sep; 11(9):1568-82. PubMed ID: 26485927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
    Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL
    Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.
    Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Zhao Y; Yan Y; Hu YJ; Wu JS; Lu WL
    Oncotarget; 2015 Nov; 6(34):36625-42. PubMed ID: 26429872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of R
    Liu JJ; Tang W; Fu M; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1947-1960. PubMed ID: 31079495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
    Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT
    Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer.
    Fu M; Tang W; Liu JJ; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
    J Drug Target; 2020 Mar; 28(3):245-258. PubMed ID: 31462111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma.
    Li XY; Zhao Y; Sun MG; Shi JF; Ju RJ; Zhang CX; Li XT; Zhao WY; Mu LM; Zeng F; Lou JN; Lu WL
    Biomaterials; 2014 Jul; 35(21):5591-604. PubMed ID: 24726749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.
    Song XL; Ju RJ; Xiao Y; Wang X; Liu S; Fu M; Liu JJ; Gu LY; Li XT; Cheng L
    Int J Nanomedicine; 2017; 12():7433-7451. PubMed ID: 29066893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer.
    Liu L; Mu LM; Yan Y; Wu JS; Hu YJ; Bu YZ; Zhang JY; Liu R; Li XQ; Lu WL
    Int J Nanomedicine; 2017; 12():4163-4176. PubMed ID: 28615943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC.
    Kong L; Zhang SM; Chu JH; Liu XZ; Zhang L; He SY; Yang SM; Ju RJ; Li XT
    Int J Nanomedicine; 2020; 15():6451-6468. PubMed ID: 32922011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
    Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
    Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
    [No Abstract]   [Full Text] [Related]  

  • 14. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
    Zhang L; Yao HJ; Yu Y; Zhang Y; Li RJ; Ju RJ; Wang XX; Sun MG; Shi JF; Lu WL
    Biomaterials; 2012 Jan; 33(2):565-82. PubMed ID: 21983136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
    Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
    Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels.
    Ju RJ; Cheng L; Qiu X; Liu S; Song XL; Peng XM; Wang T; Li CQ; Li XT
    J Drug Target; 2018 Nov; 26(9):793-805. PubMed ID: 29334266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.
    Wang XX; Li YB; Yao HJ; Ju RJ; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
    Biomaterials; 2011 Aug; 32(24):5673-87. PubMed ID: 21550109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
    Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
    Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG
    Song XL; Liu S; Jiang Y; Gu LY; Xiao Y; Wang X; Cheng L; Li XT
    Eur J Pharm Sci; 2017 Jan; 96():129-140. PubMed ID: 27644895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controllable Drug Delivery by Na+/K+ ATPase α1 Targeting Peptide Conjugated DSPE-PEG Nanocarriers for Breast Cancer.
    Yang Y; Feng Q; Ding C; Kang W; Xiao X; Yu Y; Zhou Q
    Technol Cancer Res Treat; 2021; 20():15330338211027898. PubMed ID: 34180301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.